While Syfovre’s revenue miss is no doubt disappointing, the drug remained the market leader in GA with more than 88,500 doses delivered to physicians in the third quarter, Apellis said in its ...

Apellis Pharmaceuticals is marketing Syfovre, a new treatment for patients with a leading cause of blindness. Syfovre is approved in the U.S., but Apellis' stock tanked after European regulators ...

Empaveli could achieve peak sales of $700 million by 2031, targeting C3G and IC-MPGN markets. Syfovre is expected to reach U.S. peak sales of $2 billion by 2030, driven by strong demand and ...

While the company’s topline expanded ~78% to $196.8M, it still missed Wall Street forecasts by $2.99M as Syfovre net product revenue from the U.S. fell unexpectedly. The newly launched drug for ...

The number of each atom collected is shown in the "Atoms Collected" area of the side panel. To create a molecule, make sure you have the right number of each atom and then select the correct “Create ...

Much of the growth came from Syfovre, the first Food and Drug Administration (FDA)-approved treatment for eye disorder geographic atrophy (GA). Sales of the drug more than doubled in the third ...

“The third quarter was marked by continued progress, including growth in SYFOVRE vial demand and the positive Phase 3 VALIANT study results in C3G and IC-MPGN. While SYFOVRE net sales fell short ...

Apellis Pharma has said it will seek a re-evaluation of its marketing application for Syfovre for eye disease geographic atrophy (GA) after the EMA’s human medicines committee turned it down for ...

While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.

The second portion of the registration program will include the planned injection-controlled head-to-head ARROW study against Apellis’ Syfovre, given the availability of FDA-approved GA ...

Thus, even though Syfovre has a competitive advantage over Izervay, William Blair believes both medications can thrive in light of the extensive market, significant unmet needs, and the absence of ...